D. Farrukh

3 ta ish

Tashkent Medical Park Llc, HOD Oncology Department, Tashkant, Uzbekistan

1. 75eP Mutational spectrum of KRAS, TP53, BRAF, ERBB2, and POLE in GI malignancies across diverse populations

   Nikhil Ghadyalpatil, Umut Dişel, O. Zilola +15

   MaqolaChromatin Remodeling and CancerESMO Open20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.008761

2. Abstract 2510: Comprehensive genomic profiling drives precision oncology and expands accessibility to targeted therapies in Uzbek populations

   Zilola Avazovna Olimova, Gowhar Shafi, D. Farrukh +10

   MaqolaCancer Genomics and DiagnosticsCancer Research20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.010172

3. Abstract 3141: Integrative genomic analysis reveals pharmacogenomic determinants of chemotherapy response

   D. Farrukh, Yashodhara Bhattacharya, Mohan Uttarwar +8

   MaqolaPharmacogenetics and Drug MetabolismCancer Research20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.010238